In brief
WHO announced a list of seven candidates from Qatar, Saudi Arabia, Belgium, Spain, Indonesia, China, and Armenia for director‑general. Selection will involve public forums and executive‑board interviews, with the World Health Assembly expected to appoint the new leader in May 2027. The process and final decision remain unresolved.
World Health Organization member states announced on March 15 2027 that they have nominated seven candidates to become the agency’s next director‑general. The nomination list was unveiled by the WHO, indicating a diverse slate of potential leaders.
The nominees include former Qatari health minister Hanan Mohammed Al‑Kuwari, Saudi Arabia’s WHO regional director Hanan Balkhy, Belgium’s Hans Henri P. Kluge, Spain’s Maria P. Neira, Indonesia Health Minister Budi Gunadi Sadikin, China’s Li Song, and Armenian pediatric oncologist Gevorg Tamamyan, who was nominated by Botswana. Each candidate brings a distinct portfolio ranging from national health ministries to regional WHO leadership and academic medicine.
WHO’s selection will involve a series of public forums and executive‑board interviews before the final appointment. The process aims to give member states and the public an opportunity to engage directly with the candidates.
In Geneva, the first public forum was held on Nov 18‑19 2026 at the WHO headquarters. Delegates from the organization’s 194 member states mixed with media to listen to each nominee’s vision for global health. The session marked the opening of the extended selection phase, with panel discussions exploring past achievements, proposed reforms, and how each nominee intends to tackle emerging health challenges.
Following the forum, the WHO Executive Board will reduce the list from seven to five candidates in early 2027. The board’s decision will be based on assessment criteria set by the agency, including past performance, leadership experience and strategy for future work. The five shortlisted nominees will then be evaluated in further interviews before their names are forwarded to the World Health Assembly.
Those shortlisted will participate in a second public forum scheduled for March 15 2027, again held in Geneva. This meeting is intended to provide member states with a final chance to scrutinize each contender’s proposals and to gauge their alignment with WHO’s strategic priorities. Participants will have the opportunity to ask follow‑up questions and for the nominees to clarify any ambiguities raised earlier.
The World Health Assembly, meeting later in 2027, is responsible for making the ultimate appointment. According to WHO communications, the Assembly will formally appoint the director‑general in May 2027, after reviewing the Executive Board’s recommendations. The appointed individual will assume office on August 16 2027, thereby taking over the leadership of the organization.
The WHO has highlighted that several aspects remain undecided at this juncture. For instance, it has not specified which of the seven candidates will eventually be shortlisted by the Executive Board, nor has it clarified the internal deliberations that will shape the final list of nominees. Additionally, the criteria for the Board’s evaluation, the weight assigned to public forum feedback, and the exact timeline for the interview phase are not formally detailed in the current announcement.
Meanwhile, the news of the nominations has spurred discussion among public health experts and political observers. Many are waiting to see how each nominee’s regional experience—whether as national minister, regional director, or academic leader—will translate into a global strategy. The debate includes considerations of how well each candidate can navigate WHO’s complex governance structure.
Some commentators note the presence of a medical scientist, Gevorg Tamamyan, as a significant departure from the usual exclusively administrative candidates. The inclusion of a pediatric oncologist raises questions about the potential emphasis on disease‑specific research versus broader health systems strengthening, although no official document has yet outlined how disease‑specific expertise will influence the selection weighting.
Li Song’s nomination echoes China’s growing influence within global health governance. While the candidate’s background as secretary of the All‑China Women’s Federation positions him at the intersection of national policy and gender‑focused health initiatives, the announcement stops short of linking this experience to a particular selection advantage. The extent to which the Assembly will consider national representation remains unspecified.
Uncertainties persist about which candidates will be selected, when interim interviews will occur, and how diplomatic negotiations within the Assembly will sway the final decision. Those among the seven nominees might also face unforeseen challenges that could alter the trajectory of the selection process.
Looking ahead, experts suggest the choice of director‑general will shape WHO's approach to forthcoming global health challenges, such as pandemics, climate‑related disease, and health system resilience. As geopolitical dynamics evolve, the selected leader may need to balance diverse national interests, scientific priorities, and the agency's mandate for impartial health advocacy. Establishing a clear agenda will be vital in keeping WHO's credibility.
Several member states and civil‑society groups have called for greater transparency in the selection process, demanding access to evaluation criteria, detailed timelines, and independent oversight of the Executive Board’s decision‑making. The WHO has pledged to provide periodic updates, but the exact mechanisms for stakeholder engagement remain unclear. Will those demands alter the current framework?
While official briefings have highlighted each nominee’s professional credentials, few public statements delineate specific policy positions on key issues such as universal health coverage, vaccine equity, or the response to emerging infections. Observers are watching closely how candidates articulate their readiness to confront next‑generation health crises. Diverse approaches could sway member votes.
